All In Biotech

Drug Trial Radar · NCT07055321

A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants

A Phase 1, First-in-human, Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Nov 29, 2023

Primary completion

Jul 8, 2024

Study completion Jul 8, 2024

Sponsor

Lead sponsor
Ethris GmbHIndustry
Sponsor type
Industry
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and target engagement of ETH47 in healthy participants following single intranasal and single inhaled administration

Conditions

  • Healthy Subjects

Interventions

  • ETH47Drug

    Dose level 1; single intranasal administration

  • ETH47Drug

    Dose level 2; single intranasal administration

  • ETH47Drug

    Dose level 3; single intranasal administration

  • ETH47Drug

    Dose level 4; single intranasal administration

  • ETH47Drug

    Dose level 5; single intranasal administration

  • ETH47Drug

    Dose level 1; single inhaled administration

  • ETH47Drug

    Dose level 2; single inhaled administration

  • ETH47Drug

    Dose level 3; single inhaled administration

  • ETH47Drug

    Dose level 4; single inhaled administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment-emergent adverse events (TEAEs)Time frame: From treatment until end of study (d 21)
  2. Number of serious adverse events (SAEs)Time frame: From enrollment until end of study (day 21)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRO

    Merthyr Tydfil, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.